Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep247 | Calcium and Vitamin D metabolism | ECE2015

Clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia

Cairoli Elisa , Eller-Vainicher Cristina , Rossi Diego Sergio , Beltramini Giada Anna , Russillo Antonio , Mantovani Giovanna , Spada Anna , Chiodini Iacopo

We report on the clinical and biochemical outcomes in a 20-year-old male suffering from active craniofacial monostotic fibrous dysplasia (MFD) treated with the RANK-L inhibitor, Denosumab, following unsatisfactory responses to prior long-term bisphosphonates therapy. The patient had been treated over 9 years with pamidronate (cumulative dose of 81 mg), but experienced only mild reductions in pain scores. Following initiation of Denosumab 60 mg subcutaneously, bone pain and bon...

ea0037ep806 | Pituitary: clinical | ECE2015

Psychological and neurocognitive evaluation in patients with pituitary adenoma

Sala Elisa , Zarino Barbara , Malchiodi Elena , Verrua Elisa , Carosi Giulia , Locatelli Marco , Rampini Paolo , Carrabba Giorgio , Spada Anna , Mantovani Giovanna

Reduced health-related quality of life (HRQoL) and impairment in neurocognitive functions are a possible complaint in patients with pituitary adenoma. Psychiatric comorbidities in Cushing’s disease are well known. However recent studies showed HRQoL reduction and psychiatric symptoms in patients with pituitary disease with or without hormonal excess. Aim of this study is to analyse HRQoL, psychiatric symptoms and neurocognitive functions in patients with pituitary adenoma...

ea0035p517 | Endocrine tumours and neoplasia | ECE2014

The effects of cAMP in different neuroendocrine tumorous cells: the role of Epac and PKA in cell proliferation and cell adhesion

Vitali Eleonora , Cambiaghi Valeria , Zerbi Alessandro , Peverelli Erika , Mantovani Giovanna , Loiarro Federica , Carnaghi Carlo , Spada Anna , Lania Andrea

cAMP is an ubiquitous second messenger that is implicated in the regulation of a wide variety of cell functions, including cell proliferation that is differently affected depending on the cell type. Although the effects exerted by cAMP were initially attributed to PKA activation, two exchange proteins directly activated by cAMP (Epac1/2) have been identified as cAMP targets able to mediate several cAMP effects. Aim of this study was to investigate the effect of cAMP on neuroen...

ea0035p845 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

NFPA and hypopituitarism: a retrospective analysis of 260 patients and focus on the prevalence of isolated hypoadrenalism

Carosi Giulia , Malchiodi Elena , Ferrante Emanuele , Sala Elisa , Verrua Elisa , Beck-Peccoz Paolo , Spada Anna , Mantovani Giovanna

Introduction: Non-functioning pituitary adenomas (NFPA) accounts for about 40% of all pituitary tumors. One or more anteropituitary deficiencies are present at diagnosis in 60–80% of NFPA. Hypopituitarism classically appears with the following order: GH→FSH/LH→TSH→ACTH. Aim of the study was to evaluate the incidence and the order of appearance of pituitary deficiencies in patients with NFPA.Materials and methods: We retrospectively...

ea0070aep724 | Pituitary and Neuroendocrinology | ECE2020

Metformin and everolimus: A promising combination for neuroendocrine tumors treatment

Vitali Eleonora , Boemi Ilena , Piccini Sara , Tarantola Giulia , Zerbi Alessandro , Smiroldo Valeria , Lavezzi Elisabetta , Spada Anna , Mantovani Giovanna , Lania Andrea

Treatment options for neuroendocrine tumors (NET), including everolimus, are rarely curative, as NETs frequently show resistance to medical therapy. In fact, the use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signalling. Metformin seems to have anticancer effects in neuroendocrine tumors (NETs). A recent retrospective study found longer progression-free-survival in diabetic pancreatic neuroendocrine tumo...

ea0032oc2.3 | Bone &amp; Calcium | ECE2013

Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series

Elli Francesca Marta , Barbieri Annamaria , Bordogna Paolo , Giardino Elena , Ferrante Emanuele , Beck-Peccoz Paolo , Spada Anna , Mantovani Giovanna

Progressive osseous heteroplasia (POH) is a rare autosomal dominant disorder of mesenchymal differentiation characterized by progressive heterotopic ossification (HO) of dermis, skeletal muscle and deep connective tissues. Initially HO occurs during infancy as osteoma cutis, then extends progressively into deep connective tissues during childhood. Most cases of POH are caused by paternally inherited mutations of GNAS gene. Maternal mutations as well as epigentic defec...

ea0032p824 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Role of filamin-A in the regulation of SST2 receptor localization and signalling in tumoral GH-secreting cells

Giardino Elena , Peverelli Erika , Vitali Eleonora , Cambiaghi Valeria , Lania Andrea G , Peccoz Paolo Beck , Mantovani Giovanna , Spada Anna

Somatostatin (SS) binds to different SS receptors (SSTR1–5) and SS analogues are the first choice medical treatment of GH-secreting pituitary adenomas (GH-omas). A subset of patients is resistant to SS, although the mechanisms involved in SS resistance are not fully understood. Recent studies identified specific protein–protein interactions as determinant in the regulation of receptor anchoring and signalling. Filamin A (FLNA) is a widely expressed cytoskeleton prote...

ea0029p212 | Calcium &amp; Vitamin D metabolism | ICEECE2012

Cinacalcet treatment in MEN1-associated hyperparathyroidism: a clinical trial

Filopanti M. , Verga U. , Ermetici F. , Eller-Vainicher C. , Corbetta S. , Luca P. , Beck-Peccoz P. , Spada A.

Introduction: In type 1 multiple endocrine neoplasia (MEN1), primary hyperparathyroidism (PHPT) is a challenging problem due to the high post-surgery recurrence rate. Cinacalcet is a calcimimetic agent which showed to be effective in patients in whom surgery is contraindicated or refused. In this study we assessed the efficacy and the safeness of cinacalcet in MEN1 patients, in comparison with patients with sporadic PHPT (sPHPT). Moreover, the influence of Arg990Gly CASR polym...

ea0029p216 | Calcium &amp; Vitamin D metabolism | ICEECE2012

Serum cystatin C is a reliable predictor of renal function and cardiometabolic risk in primary hyperparathyroidism

Ermetici F. , Filopanti M. , Verga U. , Passeri E. , Zelaschi R. , Raggi M. , Beck-Peccoz P. , Spada A. , Corbetta S.

Primary hyperparathyroidism (PHPT) negatively affects renal function. It is known that chronic kidney disease is a predictor of cardiometabolic diseases. Cystatin C (cystC), an alternative measure of renal function, has been associated with adverse cardiovascular events and cardiometabolic risk factors. This study was aimed to evaluate serum cystC, its relationships with PTH and cardiometabolic risk in patients with PHPT.The following parameters were mea...

ea0029p356 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Desmopressin and non steroidal anti-inflammatory drugs: a case report of severe water intoxication during replacement therapy and review of the literature

Verrua E. , Mantovani G. , Noto A. , Ferrante E. , Sala E. , Malchiodi E. , Iapichino G. , Beck-Peccoz P. , Spada A.

Context: Most of the clinical data on safety profile of desmopressin (DDAVP), i.e. an effective treatment of both polyuric conditions and bleeding disorders, originates from studies on tailoring of drug treatment, whereas few reports describe severe side effects secondary to drug–drug interaction.Objective: To describe a case of severe hyponatremia complicated with seizure and coma due to the intake of non steroidal anti-inflammatory drugs (NSAIDs) ...